Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
- 1 December 1985
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 82 (24) , 8752-8756
- https://doi.org/10.1073/pnas.82.24.8752
Abstract
The procoagulant protein F.VIII:C is noncovalently bound to von Willebrand factor (vWF) to give the factor VIII macromolecular complex. New highly purified preparations of isolated human F.VIII:C, devoid of vWF and about 500,000-fold purified, were administered to hemophilia A and von Willebrand disease (vWD) dogs to determine their hemostatic effectiveness and survival in the circulation. Two preparations of F.VIII:C were used: peak 1, with active components of Mr 185,000-280,000, and peak 2, with a single component of Mr 170,000. In hemophilic dogs, with no plasma F.VIII:C but normal vWF, both preparations immediately elevated plasma F.VIII:C to expected levels, promptly stopped induced and spontaneous hemorrhages, and gave sustained plasma levels of F.VIII:C. The isolated F.VIII:C immediately complexed with endogenous vWF in hemophilic in plasma and was eliminated biexponentially, with a half-life (t1/2) of about 9 hr. Survival of peak 2 F.VIII:C was longer than that of peak 1 material. In contrast, F.VIII:C complexed to vWF in a therapeutic concentrate administered to hemophilic dogs was eliminated biexponentially with first-phase t1/2 of 3.2 hr and second-phase t1/2 of 9 hr. In vWD dogs with no vWF and reduced F.VIII:C levels, the isolated F.VIII:C produced supernormal levels of F.VIII:C without effect on induced bleeding. It was rapidly eliminated from plasma with a t1/2 of about 1 hr, as was the complexed F.VIII:C in the concentrate. These data indicate that isolated F.VIII:C promptly complexes with vWF and in this form is highly effective in controlling hemophilic hemorrhages with good survival in plasma. Without endogenous vWF with which to complex, the F.VIII:C is promptly eliminated.This publication has 36 references indexed in Scilit:
- PROPERTIES OF FACTOR-VIII COAGULANT ACTIVITY PREPARED BY IMMUNOADSORBENT CHROMATOGRAPHY1979
- Purification of F.VIII:C by antigen-antibody chromatographyThrombosis Research, 1978
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978
- Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities.1976
- Survival of Transfused Factor VIII in Hemophilic Patients Treated with Epsilon Aminocaproic AcidTransfusion, 1976
- Molecular weight of human factor VIII procoagulant activityThrombosis Research, 1975
- Synthesis of intrinsic factor X activator. Inhibition of the function of formed activator by antibodies to factor VIII and to factor IXBiochemistry, 1970
- Molecular Forms of Antihaemophilic Globulin in Plasma, Cryoprecipitate and after Thrombin ActivationBritish Journal of Haematology, 1970
- Sequence Theories of Blood Coagulation re-evaluated with reference to Lipid–Protein InteractionsNature, 1967
- A Study of the Reaction Product of Factor VIII and Factor IX by Gel FiltrationThrombosis and Haemostasis, 1967